TACR1 and neoplasm: These NK-1R antagonists inhibit neoplastic cell proliferation [12,17,18,20] and induce apoptosis in several and different tumor cell lines in a concentration-dependent manner in NK-1R-overexpressing tumor cells [12,15,16].